Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease: A Multi-centred, Randomised, Controlled Trial
The trial, sponsored by Société des Produits Nestlé (SPN), investigates the impact of lower protein infant formula on growth rates and potential long-term health risks, including obesity and cardiovascular disease. With increasing global concerns over childhood obesity and related health issues, this study positions SPN to capitalize on a growing market for specialized infant nutrition products. The findings could enhance SPN's product portfolio and provide a competitive edge against other infant formula manufacturers. Given the rising demand for health-conscious infant nutrition, successful outcomes may lead to increased market share and potential partnerships with healthcare providers and institutions focused on pediatric health.
Indication: Infant Formula
Modality: protein therapy
Target: Lower protein intake in infant formula to modulate growth rates and long-term health outcomes.
Sponsor: Société des Produits Nestlé (SPN)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Lower protein intake in infant formula to modulate growth rates and long-term health outcomes.
View original source fields
Condition raw: Infant Formula, Growth
Condition normalized: Infant Formula, Growth
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Lower protein intake in infant formula to modulate growth rates and long-term health outcomes.
Target normalized: Lower protein intake in infant formula to modulate growth rates and long-term health outcomes.